We further demonstrated that pharmacological inhibition of COPS5/MK2 acts synergistically with sorafenib to induce ferroptosis and attenuate HCC progression, suggesting that targeting the COPS5‐MK2‐HSPB1 axis is a potential therapeutic strategy against therapy resistance in HCC. This evidence concerns the gene MAPKAPK2 and hepatocellular carcinoma.